Giant Cell Arteritis, Polymyalgia Rheumatica
Conditions
Brief summary
The purpose of this study is to delineate the association of the 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) detected vasculitis pattern of the large vessels (PET positivity) and the clinical picture of Polymyalgia Rheumatica (PMR)/Giant Cell Arteritis (GCA) .
Detailed description
Introduction: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are common inflammatory conditions. The diagnosis of PMR/GCA poses many challenges since there are no specific diagnostic tests. Recent literature emphasizes the ability of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) to assess global disease activity and/or inflammation burden. 18F-FDG PET/CT may lead to make diagnosis at an earlier stage than conventional imaging and assess response to therapy. With respect to the management of PMR/GCA, there are three significant areas of concern as follows: Vasculitis process/vascular stiffness, malignancy and osteoporosis. Methods and Analysis: Patients: All patients with the suspicion of PMR/GCR will be offered to participate in the study. The current protocol consists of 4 separate studies including: I) The association of clinical picture of PMR/GCA with PET detected vasculitis II) Evaluating validity of 18F-FDG PET/CT scan for diagnosis of PMR/GCA compared to temporal artery biopsy III) Incidence of new diagnosed malignancies in patients with PMR/GCA, or PMR like syndrome with the aim of PET/CT scan and Chest X ray/Abdominal ultrasound IV) Impact of disease process as well as steroid treatment on bone mineral density, body composition and vasculitis/vascular stiffness in PMR/GCA patients.
Interventions
OTHER18F-FDG PET/CT
18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Sponsors
Odense University Hospital
Svendborg Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
* At least five (A-E) components of the PMR diagnostic criteria, including: * A. Age ≥50 years, * B. Bilateral shoulder or hip pain, * C. Morning stiffness lasting \>45 min, * D. Elevated erythrocyte sedimentation rate (ESR), * E. Elevated C-reactive protein (CRP), * F. Disease duration \>2weeks, should be met to suspect PMR. * For GCA following criteria's must be seen: Age \> 50 years, ESR/CRP \> 50, as well as at least two symptoms related to vasculitis (scalp tenderness, vision disturbances, headache (new or changed), jaw claudication, tenderness of the temporal arteria) if patients do not simultaneously have PMR. If the patient is suspected for PMR, one cranial symptom is enough to suspect GCA.
Exclusion criteria
* Dementia * Inability to communicate in Danish * Infections or malignancy when prednisolone is permanently unsuitable * Contraindication to imaging studies (allergy to contrast materials, reduced kidney function, pregnancy and Blood Sugar (BS) \>8 mmol/l after 6 hours fasting) * Initiation of steroid treatment before the PET scan * Inability to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulated prednisolone dose within the first year after treatment initiation in patients with and without vasculitis in the large vessels | One year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Physician reported visual analogue scale (VAS) in patients with vasculitis in the large vessels (positive PET) | One year | Physician assessment of disease severity as measured on a visual analogue scale (VAS) that ranges from 0 to 100 in patients with vasculitis in the large vessels detected by PET scan. |
| Patient reported pain in patients with vasculitis in the large vessels (positive PET) | One year | Patient assessment of pain intensity as measured on a visual analogue scale (VAS) that ranges from 0 to 100, in patients with vasculitis in the large vessels detected by PET scan |
| Morning stiffness (minute) in patients with vasculitis in the large vessels (positive PET) | One year | — |
| Biochemistry results in patients with vasculitis in the large vessels (positive PET) | One year | ESR, CRP and fibrinogen |
| Number of relapses in patients with vasculitis in the large vessels (positive PET) | One year | — |
| Proportion of PET positivity (vasculitis in the large vessels as well as findings compatible with PMR) in patients with temporal artery biopsy positive. | One year | — |
| Proportion of PET negativity (no signs of vasculitis in the large vessels) in patients with temporal artery biopsy negative. | One year | — |
| Incidence of malignancies in the included patients detected by the aim of 18F-FDG PET/CT scan. | One year | — |
| Incidence of malignancies in the included patients detected by the aim of Chest X Ray plus abdominal Ultrasound. | One year | — |
| Impact of disease process and steroid treatment on Aortic Pulse Wave Velocity (PWV) | One year | — |
| Impact of disease process and steroid treatment on upper limb PWV | One year | — |
| Patient reported global visual analogue scale (VAS) in patients with vasculitis in the large vessels (positive PET) | One year | Patient global assessment of disease severity as measured on a visual analogue scale (VAS) that ranges from 0 to 100, in patients with vasculitis in the large vessels detected by PET scan |
| Impact of disease process and steroid treatment on Body Mass Index | One year | — |
| Impact of disease process and steroid treatment on T score | One year | — |
| Impact of disease process and steroid treatment on Z score | One year | — |
| Impact of disease process and steroid treatment on Lean Body Mass | One year | — |
| Impact of disease process and steroid treatment on Fat Mass | One year | — |
| Impact of disease process and steroid treatment on Bone Mineral Density | One year | — |
| Impact of disease process and steroid treatment on Bone Mineral Content | One year | — |
| Impact of disease process and steroid treatment on Fat Free Mass | One year | — |
| Impact of disease process and steroid treatment on Fat Free Mass Index | One year | — |
| Impact of disease process and steroid treatment on Fat Mass Index | One year | — |
| Impact of disease process and steroid treatment on Aortic augmentation index | One year | — |
Countries
Denmark
Contacts
Primary ContactAmir Emamifar, MD
Backup ContactInger Marie Jensen Hansen, PhD, DMSci
Outcome results
None listed